Author: Kalicińska, Elżbieta; Szymczak, Donata; Andrasiak, Iga; Bogucka-Fedorczuk, Aleksandra; Zińczuk, Aleksander; Szymański, Wojciech; Biernat, Monika; Rymko, Marcin; Semeńczuk, Grażyna; Jablonowska, Paula; Rybka, Justyna; Simon, Krzysztof; Wróbel, Tomasz
Title: Lymphocyte Subsets in Haematological Patients with COVID-19: Multicentre Prospective Study Cord-id: iqxq0fzu Document date: 2020_11_11
ID: iqxq0fzu
Snippet: The role of immune dysregulation in the course and prognosis of COVID-19 is not clearly established. In particular, immune status in specific populations such as haematological patients, who have an impaired immunological system, has not been described so far. Here, we performed a comprehensive analysis of peripheral blood lymphocyte subsets in 27 SARS-CoV-2-infected patients, including 16 patients with haematological malignancies. We identified T cell subpopulations, B cells, NK cells and TCR Î
Document: The role of immune dysregulation in the course and prognosis of COVID-19 is not clearly established. In particular, immune status in specific populations such as haematological patients, who have an impaired immunological system, has not been described so far. Here, we performed a comprehensive analysis of peripheral blood lymphocyte subsets in 27 SARS-CoV-2-infected patients, including 16 patients with haematological malignancies. We identified T cell subpopulations, B cells, NK cells and TCR α/ß and É£/Æ-expressing T cells during COVID-19 infection, with significant changes observed in immune profiles during the course of disease, especially in haematological patients. We observed an increase in activated T lymphocytes (CD3+HLA-DR+ and CD3+CD8+HLA-DR+) in the early stages of SARS-CoV-2 infection with a concomitant decrease in the CD4/CD8 ratio in haematological patients compared to non-haematological patients affected by COVID-19. We also found a decrease in É£/Æ T cells in both studied groups of patients, with lower numbers of CD25+ T cells and CD16+CD56+ NK cells in haematological patients compared to non-haematological patients with COVID-19. Our findings demonstrate, for the first time, impaired adaptive immunity in patients with haematological malignancies infected with COVID-19, resulting in impaired cellular immune responses to SARS-CoV-2. This warrants further investigation of this disease group in COVID-19 patient cohorts
Search related documents:
Co phrase search for related documents- activation marker and acute respiratory distress syndrome: 1, 2, 3
- activation marker and acute respiratory distress syndrome ards: 1, 2
- activation marker and adaptive immunity: 1, 2, 3, 4
- activation marker and liver diseases: 1
- acute myeloid leukemia and lopinavir ritonavir: 1, 2
- acute respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute respiratory distress syndrome and liver diseases: 1, 2, 3, 4, 5, 6
- acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome ards and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
- acute respiratory distress syndrome ards and liver diseases: 1, 2, 3, 4
- acute respiratory distress syndrome ards and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adaptive immunity and liver diseases: 1, 2
- adaptive immunity and lopinavir ritonavir: 1, 2
- liver diseases and lopinavir ritonavir: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date